Germany’s state-owned international public broadcaster recently seemingly endorsed Ivermectin as a treatment for COVID-19. Of course, the taxpayer-funded entity known as Deutsche Welle or “DW” isn’t a medical agency and has no authority or credentials to recommend any drug. But they certainly have reach, influenced and are backed by deep pockets. The public broadcaster makes content available in 30 languages from Hindi and Spanish to Arabic and English. Because the content created by DW’s employees are regulated by the Deutsche Welle-Act, its independent of government influence, affording more independence than perhaps available for other comparable public broadcasters. DW quietly released a “Fact Check: Effective (and Ineffective) COVID-19 Treatments.” The international media powerhouse chimed in on Ivermectin.
First, TrialSite finds it interesting that the Remdesivir conflict just gets more controversial. On the one hand, Remdesivir, supported by a series of taxpayer-supported trials via the National Institutes of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) is approved by the U.S. Food and Drug Administration (FDA). TrialSite’s critical view questioned a number of actions along the path of approval, including the modification of endpoints toward the end of the pivotal NIAID-based initial trial, leading to first its emergency use authorization.
The independent German public media offers an objective view, sharing that the drug has conditional approval in Europe as well as full approval for patients hospitalized with COVID-19 in America. They also share that the World Health Organization (WHO) recommends against the use of remdesivir (Solidarity trial). For the Remdesivir (VEKLURY) label, see here. They declare that ‘remdesivir “…efficacy has not been proved.”
On the topic of Ivermectin, the prominent public German media concern notes that WHO and the U.S. FDA advise against the drug at this point but as a counter they share the perspective of the “U.S. Frontline COVID-19 Critical Care Alliance” known as the FLCCC. According to the FLCCC meta-analysis of dozens of clinical trials, this drug has the potential to augment and support a vaccination scheme worldwide. That is vaccines, plus proper measures such as hygiene, social distancing and masks coupled with a competitive mix of treatments, preferably including low cost generic ones, and nations around the world will pull out of the pandemic.